Lennart B van Rijssen1, Lydia G M van der Geest2, Thomas L Bollen3, Marco J Bruno4, Ate van der Gaast5, Laetitia Veerbeek6, Fibo J W Ten Kate7, Olivier R C Busch8. 1. Dutch Pancreatic Cancer Group (DPCG), The Netherlands; Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands. 2. Dutch Pancreatic Cancer Group (DPCG), The Netherlands; Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. 3. Dutch Pancreatic Cancer Group (DPCG), The Netherlands; Department of Radiology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands. 4. Dutch Pancreatic Cancer Group (DPCG), The Netherlands; Department of Gastroenterology, Erasmus Medical Center, Rotterdam, The Netherlands. 5. Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands. 6. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. 7. Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. 8. Dutch Pancreatic Cancer Group (DPCG), The Netherlands; Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: o.r.busch@amc.nl.
Abstract
BACKGROUND: We evaluated national compliance to selected quality indicators from the Dutch multidisciplinary evidence-based guideline on pancreatic and periampullary carcinoma and identified areas for improvement. METHODS: Compliance to 3 selected quality indicators from the guideline was evaluated before and after implementation of the guideline in 2011: 1) adjuvant chemotherapy after tumor resection for pancreatic carcinoma, 2) discussion of the patient within a multidisciplinary team (MDT) meeting and 3) a maximum 3-week interval between final MDT meeting and start of treatment. RESULTS: In total 5086 patients with pancreatic or periampullary carcinoma were included. In 2010, 2522 patients were included and in 2012, 2564 patients. 1) Use of adjuvant chemotherapy following resection for pancreatic carcinoma increased significantly from 45% (120 out of 268) in 2010 to 54% (182 out of 336) in 2012 which was mainly caused by an increase in patients aged <75 years. 2) In 2012, 64% (896 of 1396) of patients suspected of a pancreatic or periampullary carcinoma was discussed within a MDT meeting which was higher in patients aged <75 years and patients starting treatment with curative intent. 3) In 2012, the recommended 3 weeks between final MDT meeting and start of treatment was met in 39% (141 of 363) of patients which was not influenced by patient and tumor characteristics. CONCLUSION: Compliance to three selected quality indicators in pancreatic cancer care was low in 2012. Areas for improvement were identified. Future compliance will be investigated through structured audit and feedback from the Dutch Pancreatic Cancer Audit.
BACKGROUND: We evaluated national compliance to selected quality indicators from the Dutch multidisciplinary evidence-based guideline on pancreatic and periampullary carcinoma and identified areas for improvement. METHODS: Compliance to 3 selected quality indicators from the guideline was evaluated before and after implementation of the guideline in 2011: 1) adjuvant chemotherapy after tumor resection for pancreatic carcinoma, 2) discussion of the patient within a multidisciplinary team (MDT) meeting and 3) a maximum 3-week interval between final MDT meeting and start of treatment. RESULTS: In total 5086 patients with pancreatic or periampullary carcinoma were included. In 2010, 2522 patients were included and in 2012, 2564 patients. 1) Use of adjuvant chemotherapy following resection for pancreatic carcinoma increased significantly from 45% (120 out of 268) in 2010 to 54% (182 out of 336) in 2012 which was mainly caused by an increase in patients aged <75 years. 2) In 2012, 64% (896 of 1396) of patients suspected of a pancreatic or periampullary carcinoma was discussed within a MDT meeting which was higher in patients aged <75 years and patients starting treatment with curative intent. 3) In 2012, the recommended 3 weeks between final MDT meeting and start of treatment was met in 39% (141 of 363) of patients which was not influenced by patient and tumor characteristics. CONCLUSION: Compliance to three selected quality indicators in pancreatic cancer care was low in 2012. Areas for improvement were identified. Future compliance will be investigated through structured audit and feedback from the Dutch Pancreatic Cancer Audit.
Authors: Noor L H Bekkali; Sam Murray; Lesley Winter; Vinay Sehgal; George J M Webster; Michael H Chapman; Steven Bandula; Zahir Amin; Samantha Read; Stephen P Pereira; Gavin J Johnson Journal: Frontline Gastroenterol Date: 2016-09-05
Authors: Florence Em de Rijk; Marinus A Kempeneers; Marco J Bruno; Marc Gh Besselink; Harry van Goor; Marja A Boermeester; Erwin Jm van Geenen; Jeanin E van Hooft; Hjalmar C van Santvoort; Robert C Verdonk Journal: United European Gastroenterol J Date: 2020-06-26 Impact factor: 4.623
Authors: Maikel J Bakens; Lydia G van der Geest; Magreet van Putten; Hanneke W van Laarhoven; Geert-Jan Creemers; Marc G Besselink; Valery E Lemmens; Ignace H de Hingh Journal: Cancer Med Date: 2016-09-27 Impact factor: 4.452
Authors: Malte Weinrich; Johanna Bochow; Anna-Lisa Kutsch; Guido Alsfasser; Christel Weiss; Ernst Klar; Bettina M Rau Journal: Ann Med Surg (Lond) Date: 2018-06-27
Authors: T M Mackay; F J Smits; A E J Latenstein; A Bogte; B A Bonsing; H Bos; K Bosscha; L A A Brosens; L Hol; O R C Busch; G J Creemers; W L Curvers; M den Dulk; S van Dieren; L M J W van Driel; S Festen; E J M van Geenen; L G van der Geest; D J A de Groot; J W B de Groot; N Haj Mohammad; B C M Haberkorn; J T Haver; E van der Harst; G J M Hemmink; I H de Hingh; C Hoge; M Y V Homs; N C van Huijgevoort; M A J M Jacobs; E D Kerver; M S L Liem; M Los; H Lubbinge; S A C Luelmo; V E de Meijer; L Mekenkamp; I Q Molenaar; M G H van Oijen; G A Patijn; R Quispel; L B van Rijssen; T E H Römkens; H C van Santvoort; J M J Schreinemakers; H Schut; T Seerden; M W J Stommel; A J Ten Tije; N G Venneman; R C Verdonk; J Verheij; F G I van Vilsteren; J de Vos-Geelen; A Vulink; C Wientjes; F Wit; F J Wessels; B Zonderhuis; C H van Werkhoven; J E van Hooft; C H J van Eijck; J W Wilmink; H W M van Laarhoven; M G Besselink Journal: Trials Date: 2020-04-16 Impact factor: 2.279